Indian firm files patent for Zika vaccine candidates

February 03, 2016 04:43 pm | Updated December 04, 2021 11:34 pm IST - HYDERABAD:

Krishna Ella, Chairman and Managing Director of Bharat Biotech at at a press conference in Hyderabad on Wednesday. - Photo: Mohammed Yousuf

Krishna Ella, Chairman and Managing Director of Bharat Biotech at at a press conference in Hyderabad on Wednesday. - Photo: Mohammed Yousuf

Hyderabad-based Bharat Biotech has filed for global patent of two vaccine candidates - a recombinant vaccine and an inactivated vaccine - for Zika virus.

The company announced that it could make available the inactivated vaccine in two years if the Indian Government fast-tracked the regulatory approvals once the pre-clinical trials proved to be successful.

Addressing a press conference here on Wednesday, Krishna Ella, Chairman and Managing Director of the company, said that Bharat Biotech was probably the first in the world to file for global patent for the two promising Zikavac vaccine candidates.

While the recombinant vaccine might take time, the pre-clinical testing of the inactivated vaccine in animals would be completed in five months.

He said that the company had invested over $ 150 million since its inception to build its portfolio of vaccines, which included Rotovac (rotavirus vaccine) and Typbar TCV, typhoid conjugate vaccine. He said that a patent was also filed for Chikungunya vaccine, which would be entering Phase-1 trials shortly.

Bharat Biotech Director R & D Sumathy said that work on Zika vaccine project was started in 2014 and the patent was filed in July 2015. She said that Zika fever was an unmet healthcare need in India and other countries and the potential for Zika virus epidemic was high.

Mr. Krishna Ella said the normal process for a vaccine to get commercialised would take seven years, including the clinical trials.

However, he said that the Zikavac vaccine could be made available if the Indian Government declares national emergency and moves aggressively in regulatory approvals. He said that women would be the prime target group for the vaccine, followed by adults of both the genders since the virus causes Guillain-Barre syndrome in them.

A Bharat Biotech press release said that the WHO just announced a disease linked to the Zika virus in Latin America poses a global public health emergency requiring a united response.

Zika is now present in 23 countries. Brazil, the hardest-hit country, has reported around 3,500 cases of the devastating birth defect called microcephaly. The Zika virus is spread by mosquitoes of the Aedes genus, which can breed in a pool of water as small as a bottle cap and usually bite during the day.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.